Table 1 Demographics and salient clinical features
Age (median) | 56 Years (24–80) 9 (41%) were age > / = 65 years |
|---|---|
Sex (M:F) | 17:5 (77%: 23%) |
aaCCI (median) | 6 (3–9) |
cFS (median) | 3 (2–4) |
Subsite | Oral Cavity—16 (73%) Oropharynx—6 (27%) |
Histology | SCC—18 (82%) MC—2 (9%) ACC—2 (9%) |
Stage | II or III—6 (27%) IVA—11 (50%) IVB—4 (18%) IVC—1 (5%) |
Radiation | Definitive—8 (27%) Adjuvant—16 (73%) |
Concurrent systemic therapy | Yes—12 (55%) No—10 (45%) |
Systemic therapy agents | CDDP—9 (75%) Nimotuzumab—2 (17%) Pacli + Carbo—1 (8%) |